larotrectinib

Categories
  1. EMA recommends approval of Vitrakvi (larotrectinib)

    Vitrakvi (larotrectinib) recommended by the CHMP for approval in the EU.

    EU approval OK hand gesture

    Read more »
  2. New cancer medicine targets tumour biomarkers anywhere in the body

    The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

    US flag thumbs up gesture

    Read more »
US 0